MIRA Pharmaceuticals Completes Phase 1 Dosing for Ketamir-2 with Favorable Safety Profile
Summary
MIRA Pharmaceuticals announced the successful completion of Phase 1 dosing for its drug candidate Ketamir-2, reporting favorable safety and tolerability, and plans to advance to Phase 2a for chemotherapy-induced peripheral neuropathy.
Key Events
-
Phase 1 Dosing Completed
MIRA Pharmaceuticals has completed dosing in its Phase 1 clinical trial for Ketamir-2, involving 56 healthy adult volunteers across single and multiple ascending dose cohorts.
-
Favorable Safety and Tolerability
The study reported no serious adverse events or dose-limiting toxicities at any dose level. Crucially, no clinically significant dissociative or psychotomimetic effects typically associated with ketamine were observed.
-
Advancing to Phase 2a for CIPN
The company intends to submit documentation for a Phase 2a clinical study to the FDA in the first half of 2026. This study will target chemotherapy-induced peripheral neuropathy (CIPN), an indication with no currently FDA-approved therapies.
-
Upcoming Data Presentation
MIRA Pharmaceuticals plans to present the full Phase 1 data at an upcoming scientific meeting, providing further details on the drug's pharmacokinetics and safety.
Analysis
MIRA Pharmaceuticals has successfully completed Phase 1 dosing for its proprietary drug candidate, Ketamir-2, reporting no serious adverse events or dose-limiting toxicities. This positive safety and tolerability data is a crucial de-risking step for the company's pipeline, especially for a small biotech. The absence of typical ketamine-associated dissociative effects is a significant finding, potentially broadening the drug's therapeutic window. The company's plan to submit for a Phase 2a study in the first half of 2026, targeting chemotherapy-induced peripheral neuropathy (CIPN) which currently lacks FDA-approved therapies, highlights a substantial market opportunity. This positive development provides a counter-narrative to the recent insider stock sale reported on February 18, 2026, and could boost investor confidence in the company's drug development progress.
At the time of this filing, MIRA was trading at $1.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $51.9M. The 52-week trading range was $0.73 to $2.45. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.